Exhibit 99.1 XBP Global Holdings, Inc. Reports Third Quarter 2025 Results November 14, 2025 Third Quarter 2025 Highlights IRVING, TX, November 14, 2025 (GLOBE NEWSWIRE) – XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ: XBP), a workflow automation leader leveraging decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, today announced its financial results for the quarter ended September 30, 2025. Due to the par ...

Financial Performance - Reported revenue for Q3 2025 totaled $209.1 million, a decline of 10.4% year-over-year[6] - Combined pro forma revenue for Q3 2025 was $220.4 million, a decrease of 18.1% year-over-year[7] - The net loss for the period was $305.838 million, compared to a net profit of $1.480 billion in the prior period, indicating a significant shift in financial performance[34] - Operating loss for the current period was $292.166 million, compared to a loss of $1.883 million in the previous period, highlighting operational challenges[34] - Pro Forma Revenue for Q3 2025 was $220,433 thousand, down from $269,167 thousand in Q3 2024, reflecting a decrease of approximately 18.1%[39] - Pro Forma Gross Profit for Q3 2025 was $48,328 thousand, compared to $53,872 thousand in Q3 2024, indicating a decline of about 9.4%[39] - Pro Forma Adjusted EBITDA for Q3 2025 was $24.7 million, an increase of 7.4% year-over-year[7] - Pro Forma Adjusted EBITDA for the nine months ended September 30, 2025, was $70,928 thousand, slightly down from $71,711 thousand for the same period in 2024[41] - The company reported a basic and diluted net loss per common share of $2.60 for the current period[34] - Net profit for the period from August 1, 2025, through September 30, 2025, was a loss of $305,838 thousand, compared to a profit of $1,454,658 thousand for the previous period[37] Asset and Liability Management - Total assets increased to $947.932 million as of September 30, 2025, compared to $390.421 million as of December 31, 2024, reflecting significant growth[31] - Total current liabilities amounted to $330.363 million, a decrease from $1.790 billion in the previous period, indicating improved liquidity management[31] - Cash and cash equivalents increased to $34.534 million from $11.635 million, reflecting better cash flow management[31] - The company reported a net cash increase of $20,344 thousand in cash, restricted cash, and cash equivalents, compared to a decrease of $20,174 thousand in the prior period[37] Operational Highlights - Applied Workflow Automation segment reported revenue of $189.4 million, down 14.0% year-over-year[4] - Technology segment revenue increased by 50.3% year-over-year, reaching $19.7 million[4] - Selling, general and administrative expenses rose to $17.980 million from $10.966 million, indicating increased operational costs[34] - Cash flows from operating activities for the period were $13,866 thousand, a significant improvement compared to a cash outflow of $159,942 thousand in the previous period[37] Goodwill and Impairment - Goodwill impairment recorded was $295.800 million, which may impact future earnings and asset valuations[34] - The company incurred a goodwill impairment of $295,800 thousand during the period[41] Strategic Initiatives - The acquisition of Exela BPA was finalized on July 29, 2025, with an equity valuation of $585.7 million[6] - The company is focusing on growth through client outreach and investment in new talent[3] - Future strategies include enhancing corporate governance and expanding agentic AI capabilities[3] Credit and Interest Expenses - Interest expense for the nine months ended September 30, 2025, was $89,506 thousand, compared to $80,118 thousand for the same period in 2024[41] - The company reported a provision for credit losses of $920 thousand for the period[37] - The company had cash paid for debt issuance costs amounting to $1,035 thousand during the period[37] Related Party Transactions - Related party revenue decreased to $4 thousand from $1.487 million, suggesting a decline in transactions with related entities[34]

Market Overview - The global Pulmonary Arterial Hypertension (PAH) market was valued at $7.66 billion in 2023, with an estimated compound annual growth rate of 3.3% through 2034[128]. - Sotatercept, launched in 2024, is generating approximately $1.4 billion in annualized sales, indicating a growing interest in anti-proliferative therapies for PAH[129]. Product Development - IKT-001, a prodrug of imatinib mesylate, is set to enter a Phase 2b study involving approximately 150 PAH patients, expected to initiate in Q4 2025[124][135]. - The FDA acknowledged the 505(b)(2) pathway as appropriate for IKT-001's approval, with a pre-NDA meeting confirming no additional clinical studies are needed[127]. - IKT-001 has established bioequivalence with a 300 mg dose to 230 mg of imatinib mesylate, and a 500 mg dose to 383 mg of imatinib mesylate, based on a study completed in 2023[126]. - The primary efficacy endpoint for the IMPROVE-PAH study will be the change in pulmonary vascular resistance (PVR) at Week 26[135]. - The company plans to apply for Orphan Drug Designation for IKT-001 once pre-clinical studies are complete, enhancing its market exclusivity prospects[133]. Financial Performance - Research and development expenses increased by $3,459,824 or 82.6% to $7,649,697 for the three months ended September 30, 2025, compared to $4,189,873 in the prior year[151]. - Selling, general and administrative expenses rose by $3,973,900 or 242.7% to $5,611,503 for the same period, up from $1,637,603[152]. - Net loss for the three months ended September 30, 2025, was $11,930,280, representing an increase of $6,152,214 or 106.5% from the previous year[150]. - Research and development expenses for the nine months ended September 30, 2025, totaled $23,434,243, an increase of $13,417,261 or 133.9% from $10,016,982 in 2024[157]. - Selling, general and administrative expenses for the nine months ended September 30, 2025, increased by $11,137,139 or 197.3% to $16,780,525 from $5,643,386[158]. - Interest income surged by $2,401,060 or 879.3% to $2,674,119 for the nine months ended September 30, 2025, compared to $273,059 in the prior year[160]. - The company had cash, cash equivalents, and marketable securities of $77.3 million as of September 30, 2025[163]. - The accumulated deficit reached $129.9 million as of September 30, 2025, with expectations of continued significant losses in the future[167]. - The company anticipates needing substantial additional funding to support ongoing operations and product development[165]. - The company has not generated any revenue from product sales and does not expect to do so until regulatory approval is obtained for its product candidates[165]. Cash Flow and Financing - Net cash used in operating activities for the nine months ended September 30, 2025, totaled $20,270,491, compared to $13,802,492 for the same period in 2024, reflecting a significant increase in cash outflow[172][174]. - Net cash provided by investing activities for the nine months ended September 30, 2025, was $2,151,977, up from $1,757,524 in 2024, primarily due to $41.6 million from the maturity of marketable securities[175][176]. - Net cash used in financing activities for the nine months ended September 30, 2025, was $102,359, a decrease from $3,793,209 in 2024, indicating reduced financing activity[177][178]. Merger and Acquisition - The company entered into a merger agreement with CorHepta Pharmaceuticals, resulting in the issuance of 4,979,101 shares of common stock, with contingent consideration based on performance milestones[188][189]. - The fair value of contingent consideration recognized at acquisition was adjusted, resulting in a change in fair value of $2,016,111 for the nine months ended September 30, 2025[190]. - The acquired in-process research and development asset of $7,357,294 was written off as research and development expense immediately following the acquisition[191]. - The company has not recorded a liability for contingent consideration as the achievement of performance milestones is not currently deemed probable[182][190]. Clinical Trial Costs - The total remaining contract costs for a clinical trial supply agreement as of September 30, 2025, were approximately $6.3 million, with an estimated performance period through 2029[180]. - Research and development expenses are recorded as incurred, with significant costs associated with external service providers and clinical studies[184][185].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________to _______________. Commission File Number: 001-38608 One Commerce Square, 24th FL Philadelphia, PA 19103 (Address of prin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 001-40899 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-35922 PEDEVCO Corp. (Exact name of registrant as specified in its charter) | Texas | 22-3755993 | | --- | - ...

Financial Performance - TRNR reported record quarterly revenue of $4.8 million, representing a 139% year-over-year growth[2] - The company incurred a net loss of $5.2 million, equating to a loss of $3.11 per diluted share, and an adjusted EBITDA loss of $2.9 million[2] - If the Sportstech acquisition had been included, TRNR's revenue for the quarter would have been approximately $18 million[2] - TRNR's management expressed confidence in achieving more than $80 million in revenue and profitability in Q4 on a pro forma basis[7] - Fitness product revenue for Q3 2025 reached $4,553 million, a significant increase from $1,617 million in Q3 2024, representing a growth of 181%[23] - Total revenue for the nine months ended September 30, 2025, was $7,391 million, compared to $2,997 million for the same period in 2024, marking a 147% increase[23] - Gross profit for Q3 2025 was $825 million, compared to a gross loss of $288 million in Q3 2024, indicating a turnaround in profitability[23] - The net loss attributable to common stockholders for Q3 2025 was $5,231 million, an improvement from a net loss of $7,141 million in Q3 2024[23] - Net loss for the nine months ended September 30, 2025, was $14,012, compared to a net loss of $29,172 in 2024, representing a 52% improvement[27] Acquisition and Strategic Initiatives - TRNR reiterates its full-year 2025 pro forma revenue guidance of more than $80 million, driven by the expected completion of the Sportstech acquisition[3] - The Sportstech acquisition is anticipated to close in 2025 based on achieving key closing milestones[4] - The new CFO, Caleb Morgret, is expected to accelerate the closing procedures for the Sportstech acquisition[7] - Cost savings initiatives have been initiated to leverage group synergies following the acquisition of Wattbike[5] - The company made a loan to Sportstech amounting to $5,025, indicating ongoing investment in strategic partnerships[27] Cash Flow and Liquidity - Cash and cash equivalents increased to $845 million as of September 30, 2025, up from $138 million at the end of 2024[25] - Cash and restricted cash at the end of the period was $845, up from $138 at the beginning of the period, showing a significant increase in liquidity[27] - Net cash used in operating activities decreased to $8,161 for the nine months ended September 30, 2025, from $8,909 in 2024, indicating an 8% reduction[27] - Total cash used in investing activities significantly increased to $53,490 in 2025, compared to $1,407 in 2024, reflecting a substantial rise in investment activities[27] - Net cash provided by financing activities rose to $62,248 in 2025, compared to $12,947 in 2024, marking an increase of 382%[27] Assets and Liabilities - Total assets as of September 30, 2025, were $85,438 million, significantly higher than $34,170 million at the end of 2024, reflecting a growth of 150%[25] - The company reported a total current liabilities of $30,808 million as of September 30, 2025, compared to $26,881 million at the end of 2024, an increase of 15%[25] - The accumulated deficit increased to $217,194 million as of September 30, 2025, from $202,586 million at the end of 2024[25] Research and Development - The company has invested $404 million in research and development for Q3 2025, a decrease from $2,212 million in Q3 2024, indicating a strategic shift in spending[23] - The company incurred $5,293 in stock-based compensation for the nine months ended September 30, 2025, down from $9,448 in 2024, a decrease of 44%[27] Digital Assets - The acquisition of digital assets amounted to $47,250 in 2025, indicating a strategic investment in digital growth[27] - The company reported a change in fair value of digital assets of $10,480, reflecting positive market conditions[27] - Proceeds from the issuance of convertible notes, net of issuance costs, were $52,533 in 2025, compared to $4,756 in 2024, showing a significant increase in financing through convertible debt[27]

OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Special Financial Report Pursuant to Rule 15d-2 of the Securities Exchange Act of 1934, as amended, reporting Financial Statements for the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________. OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATIO ...

Real Estate Portfolio - As of September 30, 2025, the real estate portfolio consisted of 27 assets, with 12 office properties totaling approximately 1.3 million rentable square feet at 69.8% occupancy[221] - The four multifamily properties were 85.3% occupied as of September 30, 2025[221] - The company intends to increase focus on premier multifamily properties while maintaining a presence in creative office assets[222] - CIM Group's operations emphasize local market knowledge to mitigate risks associated with real estate acquisitions[226] Financial Performance - Total revenues for the three months ended September 30, 2025, were $26.234 million, a decrease of 8.3% compared to $28.616 million for the same period in 2024[247] - Net loss for the three months ended September 30, 2025, was $12.586 million, an increase of 19.0% from a net loss of $10.576 million in 2024[247] - Funds from Operations (FFO) attributable to common stockholders for the three months ended September 30, 2025, was $(11.124) million, an improvement of approximately $17.3 million compared to $(28.420) million in 2024[251] - Total revenues for the nine months ended September 30, 2025, were $88.2 million, a decrease of $8.8 million or 9.1% compared to $97.1 million for the same period in 2024[275] - Net loss for the nine months ended September 30, 2025, was $28.0 million, compared to a net loss of $15.3 million for the same period in 2024, an increase of 82.7%[275] - FFO attributable to common stockholders was $(24.4) million for the nine months ended September 30, 2025, an improvement of $13.2 million compared to $(37.6) million for the same period in 2024[279] Revenue Breakdown - Office revenue decreased to $12.5 million for the three months ended September 30, 2025, down from $13.8 million for the same period in 2024, a decline of 9.4%[255] - Hotel revenue increased to $7.6 million for the three months ended September 30, 2025, compared to $7.1 million for the same period in 2024, an increase of 7.0%[256] - Multifamily revenue decreased to $3.9 million for the three months ended September 30, 2025, down from $4.8 million for the same period in 2024, a decline of 18.8%[257] - Lending revenue was $2.2 million for the three months ended September 30, 2025, compared to $2.7 million for the same period in 2024, a decrease of 18.5%[259] - Office revenue decreased to $37.4 million for the nine months ended September 30, 2025, down 12.1% from $42.5 million in the same period of 2024[283] - Hotel revenue increased to $31.9 million for the nine months ended September 30, 2025, up 2.4% from $31.2 million in the same period of 2024[284] - Multifamily revenue decreased to $11.9 million for the nine months ended September 30, 2025, down 20.4% from $15.0 million in the same period of 2024[286] - Lending revenue decreased to $6.7 million for the nine months ended September 30, 2025, down 15.7% from $7.9 million in the same period of 2024[287] Occupancy and Rent Metrics - Occupancy rate for the multifamily portfolio as of September 30, 2025, was 85.3%, down from 92.0% in 2024[237] - Monthly rent per occupied unit in the multifamily portfolio was $2,508 as of September 30, 2025, compared to $2,555 in 2024[237] - Hotel occupancy for the nine months ended September 30, 2025, was 75.7%, an increase from 71.4% in 2024[238] - Average Daily Rate (ADR) for the hotel was $209.93 for the nine months ended September 30, 2025, compared to $203.98 in 2024[238] Cash Flow and Expenses - Net cash provided by operating activities was $2.5 million for the nine months ended September 30, 2025, a decrease from $15.9 million in the same period of 2024[304] - Net cash used in investing activities decreased to $9.3 million for the nine months ended September 30, 2025, compared to $14.7 million in the same period of 2024[305] - Net cash provided by financing activities was $2.2 million for the nine months ended September 30, 2025, compared to net cash used of $9.4 million in the same period of 2024[306] - Total expenses increased to $114.3 million for the nine months ended September 30, 2025, up from $111.4 million for the same period in 2024, an increase of 2.6%[275] Debt and Financing - As of September 30, 2025, the company had mortgage loan agreements with outstanding balances of $475.8 million, maturing between June 7, 2026, and January 11, 2030[319] - The company executed a one-year extension on the $66.3 million 1150 Clay Mortgage, maturing on June 7, 2026, and intends to refinance it[320] - The Channel House Mortgage was extended through January 31, 2027, after a repayment of $6.0 million, reducing its balance from $87.0 million to $81.0 million[321] - The Lending Division Revolving Credit Facility has an outstanding debt of $9.3 million as of September 30, 2025, with an effective interest rate of 7.19%[325] - As of September 30, 2025, 82.3% of the company's debt, amounting to $439.5 million, was fixed rate borrowings, while 17.7%, or $94.4 million, was floating rate borrowings[343] Preferred Stock and Dividends - As of September 30, 2025, the company issued a total of 12,040,878 shares of Series A1 Preferred Stock, 8,251,657 shares of Series A Preferred Stock, and 56,857 shares of Series D Preferred Stock, raising aggregate net proceeds of $459.1 million after commissions, fees, and allocated costs[330] - The company redeemed 4,799,446 shares of Series A Preferred Stock, 3,148,815 shares of Series A1 Preferred Stock, and 8,410 shares of Series D Preferred Stock as of September 30, 2025[333] - Cumulative cash dividends for Series A1 Preferred Stock are set at an annual rate of 6.0%, while Series A Preferred Stock and Series D Preferred Stock have rates of 5.50% and 5.65%, respectively[331] - The company expects to pay dividends on Preferred Stock in arrears on a monthly basis, subject to operational results and other factors[332] - The company plans to continue satisfying some or all redemption requests for Preferred Stock in shares of Common Stock during 2025, when legally permitted[333] - The company has suspended its offering of Series A1 Preferred Stock as of September 30, 2025[329] Asset Management and Strategy - The strategy includes leveraging investor relationships to execute on the investment pipeline using an asset-light approach[223] - The company regularly evaluates each asset within its portfolio for potential dispositions to redeploy proceeds into higher-return assets[224] - The company entered into an agreement to sell its lending business for approximately $44 million, expecting net proceeds of about $31 million upon closing[243] Renovation and Development Projects - The 1910 Sunset Joint Venture, in which the company holds a 44% interest, is nearing completion of a project to build 36 multifamily units at an estimated cost of $14.7 million, with the company's share expected to be $6.5 million[310] - The 4750 Wilshire Joint Venture, with a 20% ownership interest, has incurred total costs of $28.6 million for converting an office property into 68 multifamily units, with an expected total completion cost of $31.4 million[311] - Total costs incurred for the Rooms Renovation Project at the Sheraton Grand Hotel reached $21.5 million as of September 30, 2025, with an additional $11.6 million estimated for the Lobby Renovation Project[312]

Financial Performance - Total revenue for the three months ended September 30, 2025, was $7,345, a decrease of $1,077 or 13% compared to $8,422 in the same period of 2024, primarily due to reduced CDC revenue for XpresTest[136] - Total revenue for the nine months ended September 30, 2025, was $22,056 million, a decrease of $4,374 million or 17% compared to $26,430 million in 2024[145] - Total cost of sales for the three months ended September 30, 2025, was $5,852, a decrease of $517 or 8% from $6,369 in 2024, driven by lower product costs and reduced labor due to store closures[137] - Total cost of sales for the nine months ended September 30, 2025, was $17,470 million, a decrease of $1,163 million or 6% compared to $18,633 million in 2024[146] - General and administrative expenses for the nine months ended September 30, 2025, were $10,144 million, a decrease of $5,165 million or 34% compared to $15,309 million in 2024[149] - Interest income for the nine months ended September 30, 2025, increased by $387 million to $695 million, primarily due to interest paid towards employee retention credits[153] - Foreign exchange loss for the nine months ended September 30, 2025, was $1,127 million, an increase of $917 million compared to $210 million in 2024[150] Asset and Impairment - Depreciation and amortization for the three months ended September 30, 2025, was $221, a decrease of approximately $31 or 12% compared to $252 in 2024, due to fewer long-lived assets available for depreciation[138] - The impairment of long-lived assets for the nine months ended September 30, 2025, was $122, primarily due to impairments recognized in the current period[139] Strategic Initiatives - XWELL acquired Naples Wax Center on September 12, 2023, for a purchase price of $1,624, aiming to expand its wellness platform beyond airport services[126] - XpresTest's revenue from a renewed program with the CDC is estimated to reach $15,100, following a three-year contract valued at $22.2 million[125] - As of September 30, 2025, XWELL operated 17 domestic and 11 international XpresSpa locations, enhancing its global presence[120] - The company plans to expand its retail strategy by adding more products and aligning them with service offerings, such as muscle relaxation patches[127] - XWELL aims to build capabilities for delivering health and wellness services outside of airports, which is seen as a key growth strategy[128] Financial Position and Concerns - The company reported a working capital surplus of $758 million as of September 30, 2025, down from $6,113 million as of December 31, 2024[154] - The company has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity[154] - The company is pursuing strategic partnerships to strengthen long-term profitability and improve its cash position[155] - The company must raise additional equity or debt capital to fund future operations, with no assurance of success in doing so[157] Debt and Financial Instruments - An Exchange Agreement was entered into on November 3, 2025, involving the exchange of approximately $1.6 million in Series G Preferred Stock for $3.4 million in senior secured convertible notes[129] - The company issued Senior Secured Convertible Notes on November 5, 2025, with an interest rate of 8.0% per annum, maturing in three years and four months[161] - The Company is required to maintain unencumbered cash and cash equivalents of at least $1,000,000 and deposit $1,350,000 into a segregated account[166] - The fair value of the bifurcated embedded derivative related to convertible preferred stock was estimated using a Monte Carlo simulation model[170] - The Company does not use derivative financial instruments to hedge exposures to cash-flow, market, or foreign-currency risks[169] - The Company accounts for warrants as either equity-classified or liability-classified instruments based on specific terms[171] - The fair value of the warrant liability was estimated using the Black Scholes Model, considering various weighted average assumptions[171] - There have been no material changes to the Company's critical accounting estimates from the previous report[169] Market and Economic Conditions - Ongoing geopolitical conflicts may adversely impact macroeconomic conditions and contribute to increased market volatility[172] - The number of airline travelers is volatile and subject to change based on various conditions, including travel fare prices and oil prices[172] - The Company has not identified any trends, events, or uncertainties likely to materially affect its financial condition, other than those discussed[173] - Changes in U.S. policy and government actions may impact the U.S. and global economy, tariffs, and international trade[173]